Market Intelligence, Clinical Progress, and High-Purity Reagents for Duchenne Muscular Dystrophy (DMD) Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for UTRN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | UTRN Recombinant Protein (Truncated Domains) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for binding assays. |
View UTRN Products |
| Gene Delivery | UTRN Promise-ORF / Lentivirus Full-length or micro-utrophin ORF for stable cell line generation and expression validation. |
View UTRN Products |
| Benchmark Ab | Anti-UTRN Recombinant Antibody Recombinant positive control for Western Blot, Immunofluorescence, and ELISA assays. |
View UTRN Products |
| Validator | UTRN siRNA Set For knockdown verification and specificity control in functional assays. |
View UTRN Products |
| Related Target A | DMD (Dystrophin) Functional homolog; UTRN upregulation compensates for the lack of dystrophin in DMD patients. |
View DMD Products |
| Related Target B | LAMA2 (Laminin Subunit Alpha 2) Interacts with the dystrophin-glycoprotein complex to maintain muscle membrane integrity. |
View LAMA2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Quantifying promoter activation in high-throughput screening | Lentivirus-based promoter-reporter systems for robust stable cell line construction |
| Distinguishing UTRN from DMD in expression assays | Sequence-verified antigens and highly specific recombinant antibodies to prevent cross-reactivity |
| Lack of stable positive controls for micro-utrophin delivery | High-purity, sequence-verified truncated recombinant proteins representing functional domains |
| False positive signals in upregulation assays | Validated siRNA sets included for target-specific knockdown and verification |
Live UTRN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of UTRN (Utrophin) is gaining significant traction as a mutation-independent strategy for Duchenne Muscular Dystrophy (DMD). Since utrophin is structurally and functionally homologous to dystrophin, upregulating its expression can compensate for the lack of functional dystrophin in muscle fibers. Unlike gene correction therapies, which are limited by specific patient mutations, UTRN-targeted therapies offer a universal solution for all DMD patients.
The global pipeline is shifting from early-generation small molecule transcriptional modulators to advanced modalities, including CRISPR activation (CRISPRa) systems and AAV-mediated micro-utrophin gene delivery. The next wave of R&D focuses on sustaining long-term expression of utrophin at the sarcolemma without triggering immune responses, driving the demand for highly characterized protein domains and robust cell-based validation assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CRISPR Activation (CRISPRa) | Cure Rare Disease, Academic Institutions | Duchenne Muscular Dystrophy (DMD) | Lentivirus for stable dCas9-activator cell line construction |
| Gene Therapy (AAV-Micro-Utrophin) | Solid Biosciences, Sarepta Therapeutics (Alternative pipelines) | DMD, Becker Muscular Dystrophy (BMD) | High-purity truncated protein domains for F-actin binding validation |
| Small Molecule / RNA Activators | Summit Therapeutics (Legacy), Small Biotech | DMD | High-throughput promoter activation assays using reporter lentiviruses |